Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price traded up 10.3% on Thursday . The stock traded as high as $7.85 and last traded at $7.71, with a volume of 363,886 shares trading hands. The stock had previously closed at $6.99.

Several equities analysts have recently weighed in on the company. Leerink Swann reiterated a “buy” rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, May 10th. Jefferies Group cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price objective on the stock. in a report on Wednesday, June 1st. Wedbush reiterated an “outperform” rating and set a $14.00 price objective on shares of Karyopharm Therapeutics in a report on Thursday, August 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Finally, Raymond James Financial Inc. assumed coverage on Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $17.25.

The stock has a 50 day moving average price of $7.20 and a 200 day moving average price of $7.82. The company’s market cap is $290.79 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.08. On average, equities analysts forecast that Karyopharm Therapeutics Inc. will post ($3.26) earnings per share for the current year.

In related news, major shareholder Ltd Chione sold 18,824 shares of the firm’s stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent SEC filing.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.